With FDA-approved BRAF, MEK, and pan-RAF inhibitors transforming pediatric low-grade glioma (pLGG) care, learn how molecular targeting of MAPK pathway alterations is redefining frontline treatment strategies and outcomes.
With FDA-approved BRAF, MEK, and pan-RAF inhibitors transforming pediatric low-grade glioma (pLGG) care, learn how molecular targeting of MAPK pathway alterations is redefining frontline treatment strategies and outcomes.
With nearly all pediatric low-grade glioma (pLGG) tumors driven by MAPK pathway activation, targeted therapies are redefining treatment by tailoring approaches to the tumor’s specific genetic signature.
With nearly all pediatric low-grade glioma (pLGG) tumors driven by MAPK pathway activation, targeted therapies are redefining treatment by tailoring approaches to the tumor’s specific genetic signature.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.